Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Lindbrook Capital LLC

Lindbrook Capital LLC increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 36.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,632 shares of the pharmaceutical company's stock after acquiring an additional 7,872 shares during the period. Vertex Pharmaceuticals comprises 1.2% of Lindbrook Capital LLC's investment portfolio, making the stock its 13th biggest position. Lindbrook Capital LLC's holdings in Vertex Pharmaceuticals were worth $13,781,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Groesbeck Investment Management Corp NJ raised its stake in shares of Vertex Pharmaceuticals by 1.2% in the second quarter. Groesbeck Investment Management Corp NJ now owns 1,794 shares of the pharmaceutical company's stock valued at $841,000 after acquiring an additional 21 shares in the last quarter. Mutual Advisors LLC boosted its stake in shares of Vertex Pharmaceuticals by 0.6% in the 3rd quarter. Mutual Advisors LLC now owns 3,710 shares of the pharmaceutical company's stock valued at $1,751,000 after buying an additional 21 shares during the period. Institute for Wealth Management LLC. grew its stake in Vertex Pharmaceuticals by 0.6% in the 2nd quarter. Institute for Wealth Management LLC. now owns 3,586 shares of the pharmaceutical company's stock valued at $1,681,000 after acquiring an additional 22 shares during the last quarter. Drive Wealth Management LLC increased its holdings in Vertex Pharmaceuticals by 2.0% during the 2nd quarter. Drive Wealth Management LLC now owns 1,101 shares of the pharmaceutical company's stock valued at $516,000 after acquiring an additional 22 shares in the last quarter. Finally, Daymark Wealth Partners LLC raised its position in Vertex Pharmaceuticals by 2.8% during the third quarter. Daymark Wealth Partners LLC now owns 804 shares of the pharmaceutical company's stock worth $374,000 after acquiring an additional 22 shares during the last quarter. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

VRTX has been the subject of a number of recent research reports. Needham & Company LLC reissued a "hold" rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Morgan Stanley raised their price target on Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an "equal weight" rating in a research report on Tuesday. TD Cowen increased their price objective on Vertex Pharmaceuticals from $450.00 to $500.00 and gave the company a "buy" rating in a research note on Tuesday, July 23rd. StockNews.com upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Tuesday. Finally, Guggenheim lifted their target price on Vertex Pharmaceuticals from $450.00 to $558.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eighteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $495.96.

Vertex Pharmaceuticals Stock Up 2.8 %

NASDAQ VRTX traded up $14.29 during mid-day trading on Friday, reaching $516.74. 1,259,505 shares of the company's stock traded hands, compared to its average volume of 1,171,674. The company has a fifty day simple moving average of $475.40 and a 200-day simple moving average of $468.01. Vertex Pharmaceuticals Incorporated has a 1-year low of $341.90 and a 1-year high of $519.88. The company has a market cap of $133.08 billion, a price-to-earnings ratio of -259.67 and a beta of 0.39. The company has a current ratio of 2.47, a quick ratio of 2.26 and a debt-to-equity ratio of 0.01.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period in the previous year, the company earned $3.67 earnings per share. Vertex Pharmaceuticals's quarterly revenue was up 11.6% on a year-over-year basis. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -2.04 EPS for the current year.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the sale, the director now owns 4,435 shares in the company, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the sale, the chairman now owns 9,994 shares of the company's stock, valued at $4,987,006. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total transaction of $323,000.00. Following the completion of the sale, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.